Parallel Industries (EAPH) Stock Price
Parallel Industries Price
Over the last 18 years Parallel Industries grew revenue by 9.6% annually, reaching 1.56 M USD. For Parallel Industries, the net margin of -20.8% is up versus -535.2% a few years ago.
Parallel Industries stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Parallel Industries over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Parallel Industries stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Parallel Industries's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Parallel Industries Price |
|---|---|
| 8/5/2026 | 0.00 USD |
| 8/4/2026 | 0.00 USD |
| 8/3/2026 | 0.00 USD |
| 7/30/2026 | 0.00 USD |
| 7/29/2026 | 0.00 USD |
| 7/28/2026 | 0.00 USD |
| 7/27/2026 | 0.00 USD |
| 7/24/2026 | 0.00 USD |
| 7/23/2026 | 0.00 USD |
| 7/22/2026 | 0.00 USD |
| 7/21/2026 | 0.00 USD |
| 7/20/2026 | 0.00 USD |
| 7/17/2026 | 0.00 USD |
| 7/16/2026 | 0.00 USD |
| 7/15/2026 | 0.00 USD |
| 7/14/2026 | 0.00 USD |
| 7/13/2026 | 0.00 USD |
| 7/10/2026 | 0.00 USD |
| 7/9/2026 | 0.00 USD |
| 7/8/2026 | 0.00 USD |
| 7/7/2026 | 0.00 USD |
| 7/6/2026 | 0.00 USD |
| 7/2/2026 | 0.00 USD |
| 7/1/2026 | 0.00 USD |
| 6/30/2026 | 0.00 USD |
| 6/29/2026 | 0.00 USD |
| 6/26/2026 | 0.00 USD |
| 6/25/2026 | 0.00 USD |
| 6/24/2026 | 0.00 USD |
| 6/23/2026 | 0.00 USD |
| 6/22/2026 | 0.00 USD |
| 6/18/2026 | 0.00 USD |
| 6/17/2026 | 0.00 USD |
| 6/16/2026 | 0.00 USD |
| 6/15/2026 | 0.00 USD |
| 6/12/2026 | 0.00 USD |
| 6/11/2026 | 0.00 USD |
| 6/10/2026 | 0.00 USD |
| 6/9/2026 | 0.00 USD |
| 6/8/2026 | 0.00 USD |
| 6/5/2026 | 0.00 USD |
| 6/4/2026 | 0.00 USD |
| 6/3/2026 | 0.00 USD |
Parallel Industries Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Parallel Industries Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEk USD |
|---|
| EBITk USD |
| NET INCOMEM USD |
| SHARESM |
| 2002 | 2003 | 2004 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1,000.00 | – |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 87.12 | 87.12 | 87.12 | 87.12 | 87.12 | 87.12 | 87.12 | 87.12 | 87.12 | 87.12 | 87.12 | 87.12 | 87.12 | 87.12 | 87.12 | 87.12 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Parallel Industries generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Parallel Industries retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Parallel Industries's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Parallel Industries has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Parallel Industries's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Parallel Industries stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Parallel Industries Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Parallel Industries business model & stock analysis
Parallel Industries SWOT Analysis
Strengths
Easton Pharmaceuticals Inc. has several strengths that contribute to its success in the pharmaceutical industry. These strengths include:
- Strong product portfolio with a range of prescription and over-the-counter medications
- Well-established partnerships with reputable pharmaceutical companies
- Robust distribution network allowing for widespread availability of products
- Continuous innovation and investment in research and development
- Strong financial position and healthy revenue growth
Weaknesses
Despite its strengths, Easton Pharmaceuticals Inc. also has weaknesses that could hinder its growth and profitability. These weaknesses include:
- Reliance on a limited number of key products, making the company vulnerable to market fluctuations
- Limited global presence and potential challenges in expanding into new markets
- Dependency on a few key distribution partners, posing risks for supply chain disruptions
- Potential regulatory hurdles and compliance requirements in different regions
- High competition within the pharmaceutical industry
Opportunities
Easton Pharmaceuticals Inc. can capitalize on various opportunities in the market to drive growth and maximize its potential. These opportunities include:
- Increasing demand for advanced pharmaceutical solutions and personalized medicine
- Expanding into emerging markets with rising healthcare expenditures
- Participating in strategic partnerships and collaborations to enhance product development and market reach
- Advancements in technology, such as telemedicine and e-commerce, enabling new distribution channels
- Supportive government policies and regulations favoring healthcare and pharmaceutical industry
Threats
Easton Pharmaceuticals Inc. faces certain threats that may impact its operations and market position. These threats include:
- Intense competition from both established pharmaceutical companies and generic drug manufacturers
- Increasing regulatory scrutiny and stricter compliance requirements
- Rapidly changing market dynamics and consumer preferences
- Potential patent expirations, leading to generic competition and revenue loss
- Economic downturns and uncertain global economic conditions affecting consumer spending on healthcare
Parallel Industries Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Parallel Industries Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Parallel Industries historical P/E ratio, EBIT multiple, and P/S ratio
Parallel Industries annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Parallel Industries shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Parallel Industries stock splits
Parallel Industries Analyst Rating Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| 3/21/2016 | Maintained | Buy | |
| 1/31/2016 | Maintained | Outperform | |
| 11/1/2015 | Maintained | Outperform | |
| 9/13/2015 | Upgrade | NeutralOutperform |
Parallel Industries shareholder structure
| % | Name |
|---|---|
0.00000% | |
0.00000% |
Parallel Industries Beneficial Ownership Filings (SEC 13D/G)
Parallel Industries Executives and Management Board
7 members · avg. age 53 · 17 % women
Management
John Adams (53)
President, Chief Executive Officer
Walter Folinski
Chief Financial Officer · since 2013
Neil Mellor
Chief Operating Officer
Dr. Jack Barkin
Senior Vice President, Chief Medical Officer
Susan Whyte
Vice President - Marketing
John Mitchell
Vice President - Business Development
Board of Directors
Mr. Luigi Gentile
Director
Frequently asked questions about Parallel Industries
The business model of Easton Pharmaceuticals Inc. is primarily focused on acquiring, developing, and marketing various healthcare products. With a diversified portfolio, the company collaborates with industry professionals and utilizes innovative technologies to bring novel products to market. Easton Pharmaceuticals Inc. aims to enhance human wellness and quality of life by addressing unmet medical needs and exploring potential strategic partnerships within the healthcare sector.
Easton Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
The main competitors of Easton Pharmaceuticals Inc in the market include companies such as Johnson & Johnson, Pfizer Inc, GlaxoSmithKline plc, and Novartis AG.
Easton Pharmaceuticals Inc is a renowned pharmaceutical company with a rich history and background. Established in 1997, the company has been at the forefront of developing and distributing innovative healthcare solutions. With a focus on therapeutic drugs and skincare products, Easton Pharmaceuticals has garnered a reputation for delivering high-quality treatments to consumers worldwide. The company is dedicated to research and development, working closely with medical professionals to address unmet needs in various therapeutic areas. Easton Pharmaceuticals Inc's commitment to excellence and dedication to improving global health has propelled its success and solidified its position in the pharmaceutical industry.
Easton Pharmaceuticals Inc has achieved significant milestones since its inception. The company has successfully expanded its product portfolio to include a wide range of pharmaceuticals and healthcare products. Easton Pharmaceuticals Inc has also established strategic partnerships and collaborations with leading industry players, enhancing its market presence and capabilities. Furthermore, the company has demonstrated continuous growth in revenue and shareholder value through its successful business operations. With a strong commitment to innovation and quality, Easton Pharmaceuticals Inc continues to achieve remarkable milestones and advance in the pharmaceutical industry.
Easton Pharmaceuticals Inc is primarily present in North America, with a strong focus on Canada and the United States. As a pharmaceutical company, Easton Pharmaceuticals Inc operates within these countries and regions, actively engaging in the development, marketing, and distribution of various healthcare products. With its headquarters located in Toronto, Canada, Easton Pharmaceuticals Inc has established a reputable presence in the North American pharmaceutical market, while continually seeking opportunities for growth and expansion within these regions.
Easton Pharmaceuticals Inc represents a strong commitment to innovation, growth, and excellence in the pharmaceutical industry. The company's core values include integrity, transparency, and a customer-centric approach. With a focus on delivering high-quality healthcare solutions, Easton Pharmaceuticals Inc strives to improve patient outcomes and enhance well-being. The company embraces a corporate philosophy driven by research and development, fostering strategic partnerships, and expanding its global footprint. By combining scientific expertise with a dedication to ethical business practices, Easton Pharmaceuticals Inc aims to pave the way for advanced pharmaceutical solutions that meet the evolving needs of the healthcare market.
Converted at the current exchange rate, the Parallel Industries share trades at 0.00 EUR (0.00 USD).
Easton Pharmaceuticals Inc is a Canadian company specializing in the development and marketing of proprietary drugs, medical devices, and diagnostic products. The company operates in multiple sectors and offers a wide range of products. One of Easton Pharmaceuticals' sectors is the development of women's drugs. The company has focused on developing products for the treatment of cervical cancer and HPV. It has signed an exclusive licensing agreement with a leading European pharmaceutical company to develop a series of new HPV tests and treatments. In another sector, the company offers products for the treatment of pain and inflammation. This includes the medication "Nasutra," an effective natural remedy used for erectile dysfunction and sexual dysfunction. Easton Pharmaceuticals has also developed tissue repair technology to help heal injuries and wounds. Additionally, the company specializes in the development of medical devices. This includes a new coating process used in the production of medical devices and implants. The company has also developed a series of diagnostic products that help detect diseases such as lung cancer, breast cancer, and prostate cancer early. Another significant business area for Easton Pharmaceuticals is the marketing of various pharmaceutical products in Canada and the global market. This includes a wide range of prescription medications used in various therapy areas such as pain management, neurology, oncology, and gastroenterology. To manage and coordinate these different sectors, the company has built a strong leadership team. It relies on effective teamwork based on a combination of expertise and critical skills. The focus on quality and customer orientation is another important factor contributing to the success of Easton Pharmaceuticals. In addition to these sectors, the company also has a vision focused on innovation and research. Easton Pharmaceuticals recognizes the close connection between the pharmaceutical industry and the healthcare sector as a whole. Therefore, the company's goal is to identify and leverage research and development opportunities to develop innovative and groundbreaking products. Overall, Easton Pharmaceuticals has a diverse business model focused on the development and marketing of innovative products to promote people's health and well-being. Through leadership by an experienced team, a focus on quality and customer orientation, and investment in research and innovation, the company is on a path to success in the pharmaceutical industry.
The revenue cannot currently be calculated for Parallel Industries.
The profit cannot currently be calculated for Parallel Industries.
The P/E ratio cannot be calculated for Parallel Industries at the moment.
The P/S cannot be calculated for Parallel Industries currently.
The Eulerpool Quality Score for Parallel Industries is 1/10.
The ISIN of Parallel Industries is US2777741057. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Parallel Industries is A1CUUH. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Parallel Industries is EAPH. The ticker symbol is used to trade Parallel Industries shares on the stock exchange.
Parallel Industries paid dividends every year for the past 0 years.
Parallel Industries is assigned to the 'Health' sector.
The dividends of Parallel Industries are distributed in USD.
Parallel Industries stock
Parallel Industries Peer Group
Parallel Industries Ticker
Parallel Industries FIGI
All fundamentals and in-depth analysis of Parallel Industries
Our stock analysis for Parallel Industries stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Parallel Industries. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.